Diagnosis of Epilepsy Market Latest Devices, Technology, Diagnosis and Global Research Report 2020

Global Epilepsy Market Growth Research Report: by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Region – Forecast till 2023

The Epilepsy Market Growth report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report

Major Key Players

To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. Due to the increasing strategic partnerships, the structure of the market is changing rapidly. Besides, the growing competition in the market is encouraging multinational companies to acquire small yet promising companies operating in the developing markets.

LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), and Abbott Laboratories (U.S.).

Market Segmentation:

The global Epilepsy Market Growth is segmented by condition, diagnosis & treatment, and end-user.

By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the Epilepsy Market Growth.

By diagnosis & treatment, the treatment segment held 66.2% share of the Epilepsy Market Growth in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.

By end-user, hospitals were the largest segment of the market with a valuation of USD 1,739.22 million in 2017. It is projected to exhibit a stellar 8.29% CAGR over the forecast period. On the other hand, clinics can showcase higher CAGR of 8.93% during the assessment period owing to clinics being a preferred center for diagnosis and treatment. In addition, adoption of latest equipment by doctors to provide excellent patient care can spur the growth of the segment.

Geographically, the global Epilepsy Market Growth has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Browse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/epilepsy-market-7730

About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

+1 646 845 9312 | Email: sales@marketresearchfuture.com